Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Should You Buy?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped up prior to trading on Tuesday . The stock had previously closed at $20.75, but opened at $21.7899. Chugai Pharmaceutical shares last traded at $20.8345, with a volume of 12,930 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CHGCY shares. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Finally, Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 0.5%

The stock has a market cap of $68.61 billion, a PE ratio of 22.66 and a beta of 0.59. The stock has a 50-day moving average of $21.83 and a 200 day moving average of $24.67.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. Research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.